Searched for
AUROBINDO PHARMA SALES
Stocks in news: Infosys, HDFC Bank, Jio Financial, IRFC, NCC and Blue DartIndian equity benchmarks experienced a decline over two sessions due to profit booking and rising oil prices. The Nifty 50 index closed dow...- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
- Stocks in news: HDFC Bank, Ola Electric Mobility, NBCC and Knowledge Realty TrustIndian equity markets closed higher on Friday, ending a losing streak with IT stock gains. HDFC Bank's CEO will not seek reappointment, whi...
- Indian pharma has little reason to fear TrumpUS tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Aurobindo Pharma Q1 results: Net profit jumps 61% at Rs 919 croreRevenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker sa...
- Aurobindo plans domestic formulation foray, sets 1000 cr sales target in next 3yrsAurobindo Pharma is largely an export oriented drug maker, while it does have an India business which is business-to-business (B2B) involvi...
- Buy Aurobindo Pharma, target price Rs 560: Suruchi KapoorThe analyst suggested a stoploss at Rs 475 .
- Sell Aurobindo Pharma, price target Rs 440: Manas JaiswalThe analyst suggested a stoploss at Rs 486 .
- Buy Aurobindo Pharma, price target Rs 510: Manas JaiswalThe analyst suggested a stop loss at Rs 465.
- Buy Aurobindo Pharma, price target Rs 495: CK NarayanThe analyst suggested a stop loss at Rs 472.
- Sell Aurobindo Pharma, target Rs 540: Manas JaiswalSell Aurobindo Pharma Ltd. at a price target of Rs 540 and a stoploss at Rs 595 from entry point.
- Sell Aurobindo Pharma, target Rs 584: Dr CK NarayanSell Aurobindo Pharma Ltd. at a price target of Rs 584.0 and a stoploss at Rs 603 from entry point.
- Buy Aurobindo Pharma, target Rs 790: Dr CK NarayanBuy Aurobindo Pharma Ltd. at a price target of Rs 790.0 and a stoploss at Rs 765 from entry point.
- Buy Aurobindo Pharma, target Rs 850: Kunal BothraBuy Aurobindo Pharma at a price target of Rs 850 and a stop loss at Rs 750 from the entry point.
- Buy Aurobindo Pharma, target Rs 785: Shrikant ChouhanBuy Aurobindo Pharma at a price target of Rs 785 and a stop loss at Rs 732 from entry point.
- Aurobindo Pharma gets FDA nod for rosuvastatin calcium tabsAurobindo Pharma has received final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering choleste...
- Aurobindo Pharma Q1 net loss widens 4.97% at Rs 128.91 croreAurobindo Pharma today reported a 4.97 per cent widening of its consolidated net loss to Rs 128.91 crore for the quarter ended June 30, 201...
- Aurobindo’s Chinese gamble may pay offAfter three consecutive years of loss, Aurobindo Pharma is cutting loose its bleeding Chinese pharma subsidiary Aurobindo Tongling, while s...
- Aurobindo Pharma to divest Chinese armHyderabad-based Aurobindo Pharma has decided to disinvest its loss-making subsidiary in China while acquiring a small manufacturing unit in...
Load More
